Michael D Wagener
Stellar Bio molecular Research (SBR) and FCTI, Germany
Scientific Tracks Abstracts: J Nephrol Ther
Many prostate cancer patients use therapies promoted as literal alternatives to conventional medical care. Such â??alternativeâ? modalities are very often unproven or were studied and found worthless. These can be harmful. An even greater proportion of cancer patients use â??complementaryâ? treatments along with mainstream cancer treatment. Most are helpful adjunctive approaches that control symptoms and enhance quality of life. This review describes alternative as well as complementary therapies commonly used today by prostate cancer patients. Herbal remedies also are discussed. Evidence regarding the efficacy and safety of Complementary/Alternative Medicine (CAM) is reviewed, and implications for oncologists are discussed. To encourage open communication of CAM use by patients, oncologists should be knowledgeable about the most popular remedies and know where to find reliable information for themselves and for their patients.
Michael D Wagener received a Medical Degree from the University of Berlin, Germany, in 1991. During his Post-graduate training, he was trained in General Internal Medicine, Pneumology and Allergology in Davos (Switzerland). He received board certification in General Internal Medicine, Allergology and Pharmaceutical Medicine, and Neuraltherapy. In 1997, he joined Eli Lilly as a Clinical Research Physician, in 2005 Novartis Pharma in Basel and in 2009 he Became Chief Medical Officer of AC Immune in Lausanne (Switzerland). Since 2000, he was a member of the Executive Board of the Swiss Association of Pharmaceutical Medicine (SGPM) and in 2002 to 2008 he was elected as President of this organization. Since 2010, he is the Owner of an “Antiaging and Complementary Medicine Center” in Basel.
Journal of Nephrology & Therapeutics received 784 citations as per Google Scholar report
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 